公开(公告)号：US6010699A

公开(公告)日：2000-01-04

申请号：US815941

申请日：1997-03-13

申请人： Shigeru Honda ,  Noriko Watanabe ,  Takahiro Ogawa

发明人： Shigeru Honda ,  Noriko Watanabe ,  Takahiro Ogawa

IPC分类号： A61K38/49 ,  A61K38/57 ,  A61P27/10 ,  A61K38/16

CPC分类号： A61K38/49 ,  A61K38/57

摘要： A method for controlling axial length, comprising administering a pharmaceutically effective amount of a TGF-.beta. regulating substance. More particularly, a method for inhibiting axial elongation and a method for the prophylaxis and treatment of myopia, both comprising administering a TGF-.beta. activator, specifically a plasminogen activator. A method for elongation of axial length and a method for the prophylaxis and treatment of hyperopia, both comprising administering a TGF-.beta. activation inhibitor, particularly a plasminogen activator inhibitor. The method for controlling axial length of the present invention is extremely useful for the prophylaxis and treatment of myopia or hyperopia. It is also useful for preparing experimental model animals having eyes with complete axial myopia or hyperopia exclusive of refractive myopia or hyperopia.

摘要翻译： 一种用于控制轴向长度的方法，包括施用药学上有效量的TGF-β调节物质。 更具体地说，一种抑制轴向伸长的方法和一种预防和治疗近视的方法，包括给予TGF-β激活剂，特别是施用纤溶酶原激活剂。 一种延长轴向长度的方法和一种预防和治疗远视的方法，其包括施用TGF-β激活抑制剂，特别是纤溶酶原激活物抑制剂。 用于控制本发明的轴向长度的方法对于预防和治疗近视或远视非常有用。 制备具有完全轴向近视或远视的实验模型动物，不包括屈光性近视或远视。

公开(公告)号：US5830913A

公开(公告)日：1998-11-03

申请号：US747647

申请日：1996-11-13

申请人： Takahiro Ogawa ,  Noriko Watanabe ,  Yasushi Okumura

发明人： Takahiro Ogawa ,  Noriko Watanabe ,  Yasushi Okumura

IPC分类号： A61K9/08 ,  A61K31/19 ,  A61K31/192 ,  A61P27/02 ,  A61P27/04 ,  C07C309/58

CPC分类号： A61K31/192

摘要： There is disclosed a pharmaceutical composition for preventing or treating dry eye or a disease caused therefrom which comprises as an active ingredient an effective amount of sulfodehydroabietic acid or a pharmacologically acceptable salt thereof. There are also disclosed a method and device for preventing or treating dry eye or a disease caused therefrom.

摘要翻译： 公开了一种用于预防或治疗干眼症或其引起的疾病的药物组合物，其包含作为活性成分的有效量的磺基脱氢松香酸或其药理学上可接受的盐。 还公开了一种用于预防或治疗干眼症或由此引起的疾病的方法和装置。

公开(公告)号：US06268359B1

公开(公告)日：2001-07-31

申请号：US09601216

申请日：2000-07-28

申请人： Takahiro Ogawa ,  Noriko Watanabe ,  Mitsunori Waki

发明人： Takahiro Ogawa ,  Noriko Watanabe ,  Mitsunori Waki

IPC分类号： A61K3155

CPC分类号： A61K31/00 ,  A61K31/55

摘要： A pharmaceutical composition for preventing or treating visual function disorders caused by ocular circulatory disorders (for example, ocular hypertension and glaucoma) and visual function disorders based on ciliary tension (for example, myopia) whose active component is a vasopressin antagonist.

摘要翻译： 一种用于预防或治疗由眼部循环障碍（例如眼睛高血压和青光眼）引起的视觉功能障碍的药物组合物和基于睫状肌张力的视觉功能障碍（例如近视），其活性成分是血管加压素拮抗剂。

公开(公告)号：US06451799B1

公开(公告)日：2002-09-17

申请号：US09297197

申请日：1999-04-27

申请人： Takahiro Ogawa ,  Noriko Watanabe ,  Mitsunori Waki

发明人： Takahiro Ogawa ,  Noriko Watanabe ,  Mitsunori Waki

IPC分类号： A61K3150

CPC分类号： A61K31/4439 ,  A61K31/496 ,  A61K31/551 ,  Y10S514/912 ,  Y10S514/913

摘要： An agent for ameliorating ocular circulatory disorder containing a 1,4-dihydropyridine derivative of the formula (I) wherein each symbol is as defined in the specification, or an acid addition salt thereof as an active ingredient. The agent for ameliorating ocular circulatory disorder containing the compound of the above formula (I) increases optic disc blood flow of normal eye particularly by instillation, and inhibits vasocontraction of retinal blood vessel, decrease in optic disc blood flow and attenuation of the amplitude of VEP caused by ET-1, without increasing the intraocular pressure. Therefore, the inventive compound is suggested to be effective as a therapeutic agent against, from among the types of glaucoma, particularly normal tension glaucoma caused by ocular circulation disorder and retinitis pigmentosa, macular degeneration, ischemic optic neuropathy, iridocyclitis, retinal artery occlusion, retinal vein occlusion, diabetic retinopathy, ischemic optic neuropathy, retinochoroidal disease following choroidal lesion, retinochoroidal disease associated with systemic disease, and the like.

摘要翻译： 一种用于改善含有式（I）的1,4-二氢吡啶衍生物的眼部循环障碍的药剂，其中每个符号如说明书中所定义，或其酸加成盐作为活性成分。 用于改善含有上述式（I）化合物的眼部循环障碍的药物特别是通过滴注增加正常眼的视盘血流量，并且抑制视网膜血管的血管收缩，视盘血流的减少和VEP的振幅衰减 由ET-1引起，不增加眼内压。 因此，本发明化合物被认为是有效的，作为青光眼的类型，特别是由眼部循环障碍和色素性视网膜炎引起的正常的紧张性青光眼，黄斑变性，缺血性视神经病，虹膜睫状体炎，视网膜动脉闭塞，视网膜 静脉闭塞，糖尿病性视网膜病变，缺血性视神经病变，脉络膜损伤后的视网膜下疾病，与全身性疾病相关的视网膜激素疾病等。

公开(公告)号：US5942487A

公开(公告)日：1999-08-24

申请号：US976088

申请日：1997-11-21

申请人： Takahiro Ogawa ,  Hideki Tokushige ,  Noriko Watanabe

发明人： Takahiro Ogawa ,  Hideki Tokushige ,  Noriko Watanabe

IPC分类号： A61K38/00 ,  A61K38/18 ,  A61K38/21 ,  A61K38/27 ,  A61P27/02 ,  C07K14/52 ,  A61K31/00

CPC分类号： A61K38/18 ,  A61K38/19 ,  A61K38/28 ,  A61K38/30 ,  Y10S514/912

摘要： A pharmaceutical composition comprising a stem cell factor (SCF) is administered systemically or locally, preferably administered locally to the eye surface to promote the healing of corneal disorder or injured part in comparison with untreated control.

摘要翻译： 包括干细胞因子（SCF）的药物组合物全身或局部施用，优选与眼部表面局部施用以促进角膜障碍或损伤部位的愈合，与未处理的对照相比。

公开(公告)号：US5952338A

公开(公告)日：1999-09-14

申请号：US886270

申请日：1997-07-01

申请人： Toshiharu Tsuboi ,  Noriko Watanabe ,  Takahiro Ogawa ,  Mitsuyoshi Isaka ,  Mitsunori Waki

发明人： Toshiharu Tsuboi ,  Noriko Watanabe ,  Takahiro Ogawa ,  Mitsuyoshi Isaka ,  Mitsunori Waki

IPC分类号： A61K31/436 ,  A61K31/44

CPC分类号： A61K31/436 ,  Y10S514/912

摘要： An agent for the prophylaxis and treatment of disturbance of visual function, which comprises a compound of the formula �I! ##STR1## wherein A ring is optionally substituted;R.sub.1 is a hydrogen or an optionally protected amino; andR.sub.2 is a group capable of releasing a proton,or a salt thereof. The agent for the prophylaxis and treatment of disturbance of visual function of the present invention has superior preventive and therapeutic effect on asthenopia, and shows suppression of axial elongation, suppression of degradation of retinal functions and retinal function-recovery action. Hence, the agent can be advantageously used as a clinically applicable agent for the prophylaxis and treatment of disturbance of visual function.

摘要翻译： 一种用于预防和治疗视功能紊乱的药剂，其包含其中A环任选被取代的式[I]化合物; R1是氢或任选被保护的氨基; R2是能够释放质子的基团，或其盐。 本发明的预防和治疗视功能紊乱的药剂对眼疲劳具有优异的预防和治疗作用，并且显示出轴向伸长的抑制，抑制视网膜功能退化和视网膜功能恢复作用。 因此，该试剂可以有利地用作临床适用的预防和治疗视功能障碍的药剂。

公开(公告)号：US08494149B2

公开(公告)日：2013-07-23

申请号：US12096698

申请日：2007-01-30

申请人： Noriko Watanabe ,  Shinichiro Kamei ,  Kaichiro Hatazaki ,  Shinichi Ando ,  Takahiro Okonogi ,  Hiroto Teranishi

发明人： Noriko Watanabe ,  Shinichiro Kamei ,  Kaichiro Hatazaki ,  Shinichi Ando ,  Takahiro Okonogi ,  Hiroto Teranishi

IPC分类号： H04M3/00 ,  H04M1/64

CPC分类号： H04M3/5175 ,  H04M3/42221

摘要： It is possible to efficiently evaluate utterance while ensuring the effectiveness of the result of the evaluation. A selection unit 4 selects recognition data, which is used in agent evaluation from a data storage unit 7, from recognition data generated by a voice recognition unit 6 on the basis of voice data of utterance by applying a selection operation corresponding to evaluation viewpoint information with reference to an evaluation viewpoint management table 2 through an evaluation viewpoint management unit 3. An evaluation unit 5 displays recognition data and plays the voice data by an evaluation viewpoint management unit 3 by applying an output operation corresponding to evaluation viewpoint information with reference to an evaluation viewpoint management table 2.

摘要翻译： 可以有效地评价话语，同时确保评估结果的有效性。 选择单元4根据语音识别单元6生成的识别数据，从数据存储单元7中选择用于代理评估的识别数据，通过应用与评价视点信息相对应的选择操作，基于话音语音数据， 通过评价视点管理部3对评价视点管理表2进行参照。评价部5通过评价视点管理部3对参照评价视点管理部3的评价视点信息对应的输出动作进行评价，显示识别数据和播放声音数据 视点管理表2。

公开(公告)号：US08049859B2

公开(公告)日：2011-11-01

申请号：US12090888

申请日：2006-09-14

申请人： Noriko Watanabe ,  Hidenori Kihara

发明人： Noriko Watanabe ,  Hidenori Kihara

IPC分类号： G02F1/1339 ,  G02F1/1333

CPC分类号： G02F1/1339 ,  G02F1/133305 ,  G02F1/133371 ,  G02F1/13394 ,  G02F2001/133388

摘要： A liquid crystal display device includes a first flexible substrate and a second flexible substrate, a liquid crystal layer sealed between the first substrate and the second substrate by a frame-shaped sealing member, a display area located inside the sealing member, a non-display area located outside the display area and a plurality of spacers interposed between the first substrate and the second substrate. A relief area in which a gap between the first substrate and the second substrate is larger than that in the display area is provided in at least a portion of the non-display area.

摘要翻译： 液晶显示装置包括第一柔性基板和第二柔性基板，通过框状密封部件密封在第一基板和第二基板之间的液晶层，位于密封部件内部的显示区域，非显示部 位于显示区域外部的多个间隔物和插入在第一基板和第二基板之间的多个间隔物。 在非显示区域的至少一部分中设置有其中第一基板和第二基板之间的间隙大于显示区域中的间隙的释放区域。

公开(公告)号：US07940366B2

公开(公告)日：2011-05-10

申请号：US12091343

申请日：2006-06-30

申请人： Noriko Watanabe

发明人： Noriko Watanabe

IPC分类号： G02F1/1339 ,  G02F1/1345

CPC分类号： G02F1/1339 ,  G02F1/133305 ,  G02F1/13452 ,  H01L27/3276 ,  H01L51/524 ,  H01L51/5246 ,  H01L2251/5338

摘要： A display device is provided with a sealing member for sealing a liquid crystal layer between a flexible first substrate and a second substrate, a mounting region provided in a portion of the first substrate outside a display area in which the liquid crystal layer is sealed, the mounting region mounting a circuit component on at least a portion thereof, wherein the second substrate includes an extending region extending to face the mounting region and an adhesive arranged to bond the extending region and the mounting region is provided in at least a portion of a space between the extending region and the mounting region.

摘要翻译： 显示装置设置有用于密封柔性第一基板和第二基板之间的液晶层的密封构件，设置在第一基板的部分中的液晶层被密封的显示区域的安装区域， 安装区域在其至少一部分上安装电路部件，其中第二基板包括延伸到面对安装区域的延伸区域，并且布置成将延伸区域和安装区域结合的粘合剂设置在空间的至少一部分中 在延伸区域和安装区域之间。

公开(公告)号：US07244476B2

公开(公告)日：2007-07-17

申请号：US10902828

申请日：2004-08-02

申请人： Yukihiro Sumida ,  Takashi Sato ,  Hidenori Kihara ,  Noriko Watanabe

发明人： Yukihiro Sumida ,  Takashi Sato ,  Hidenori Kihara ,  Noriko Watanabe

IPC分类号： G02F1/1333

CPC分类号： G02F1/1335 ,  G02F1/133504 ,  G02F1/133526 ,  Y10T428/10 ,  Y10T428/1059 ,  Y10T428/1481 ,  Y10T428/24355

摘要： Adhesive layers are formed on the two opposing surfaces of a transparent support. At least one of the adhesive layers is made of a material of which the cured state may be changed. The adhesive layer is irradiated with light and a lens sheet is then pressed against the adhesive layer. The adhesive layer is cured. In this illustrative way, a laminate film of the lens sheet fixed to the transparent support via the adhesive layer may be obtained. The laminate film may be bonded to a polarizing plate on the viewer's side of a liquid crystal display element via the other adhesive layer.

摘要翻译： 粘合层形成在透明支撑体的两个相对的表面上。 粘合剂层中的至少一个由可以改变固化状态的材料制成。 用光照射粘合剂层，然后将透镜片压在粘合剂层上。 粘合层固化。 以这种说明的方式，可以获得通过粘合剂层固定到透明支撑体的透镜片的层压膜。 层叠膜可以经由另一粘合层与液晶显示元件的观察者侧的偏振片接合。